{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:46:45Z","timestamp":1791812805764,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhejiang Science and Technology Plan of Traditional Chinese Medicine","award":["2026ZL0109"],"award-info":[{"award-number":["2026ZL0109"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13972-6","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:24:24Z","timestamp":1784100264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical biomarkers associated with Pneumocystis jirovecii pneumonia among dermatology patients receiving systemic immunosuppression: a single-center retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Wenting","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-e","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"13972_CR1","doi-asserted-by":"crossref","unstructured":"McMullan B, Kim HY, Alastruey-Izquierdo A, Tacconelli E, Dao A, Oladele R, et al. Features and global impact of invasive fungal infections caused by Pneumocystis jirovecii: A systematic review to inform the World Health Organization fungal priority pathogens list. Med Mycol. 2024;62(6).","DOI":"10.1093\/mmy\/myae038"},{"issue":"1","key":"13972_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jaad.2025.02.045","volume":"93","author":"S Rahman","year":"2025","unstructured":"Rahman S, Gniadecki R. Pneumocystis jirovecii pneumonia prophylaxis in patients with chronic inflammatory skin diseases: Systematic review and meta-analysis. J Am Acad Dermatol. 2025;93(1):230\u20131.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"13972_CR3","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","volume":"24","author":"M Reinwald","year":"2018","unstructured":"Reinwald M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24(Suppl 2):S53\u201370.","journal-title":"Clin Microbiol Infect"},{"key":"13972_CR4","doi-asserted-by":"publisher","first-page":"152106","DOI":"10.1016\/j.semarthrit.2022.152106","volume":"57","author":"B Boone","year":"2022","unstructured":"Boone B, et al. Rates of Pneumocystis jirovecii pneumonia and prophylaxis prescribing patterns in a large electronic health record cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2022;57:152106.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"13972_CR5","first-page":"520","volume":"20","author":"CM Foschi","year":"2022","unstructured":"Foschi CM, Maloney C, Amber KT. Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris. J Dtsch Dermatol Ges. 2022;20(4):520\u20131.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"13972_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/ijd.13231","volume":"55","author":"TM Gonzalez Santiago","year":"2016","unstructured":"Gonzalez Santiago TM, et al. Pneumocystis jiroveci pneumonia in patients treated with systemic immunosuppressive agents for dermatologic conditions: a systematic review with recommendations for prophylaxis. Int J Dermatol. 2016;55(8):823\u201330.","journal-title":"Int J Dermatol"},{"issue":"4","key":"13972_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/23744235.2018.1558368","volume":"51","author":"T Matsumoto","year":"2019","unstructured":"Matsumoto T, et al. Risk factors for pneumocystis pneumonia onset in HIV-negative patients treated with high-dose systemic corticosteroids. Infect Dis (Lond). 2019;51(4):305\u20137.","journal-title":"Infect Dis (Lond)"},{"issue":"1","key":"13972_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/sji.12506","volume":"85","author":"G Azizi","year":"2017","unstructured":"Azizi G, et al. Approach to the Management of Autoimmunity in Primary Immunodeficiency. Scand J Immunol. 2017;85(1):13\u201329.","journal-title":"Scand J Immunol"},{"issue":"1","key":"13972_CR9","doi-asserted-by":"publisher","first-page":"107019","DOI":"10.1016\/j.ijantimicag.2023.107019","volume":"63","author":"TY Liao","year":"2024","unstructured":"Liao TY, et al. Clinical significance of mutations in dihydropteroate synthase in Pneumocystis jirovecii pneumonia among non-HIV-infected patients. Int J Antimicrob Agents. 2024;63(1):107019.","journal-title":"Int J Antimicrob Agents"},{"key":"13972_CR10","doi-asserted-by":"crossref","unstructured":"Wiedermann CJ. Hypoalbuminemia as surrogate and culprit of infections. Int J Mol Sci. 2021;22(9).","DOI":"10.3390\/ijms22094496"},{"key":"13972_CR11","doi-asserted-by":"crossref","unstructured":"Gremese E, Ferraccioli G, Alivernini S, Tolusso B. Serum albumin levels: A biomarker to be repurposed in different disease settings in clinical practice. J Clin Med. 2023;12(18).","DOI":"10.3390\/jcm12186017"},{"issue":"2","key":"13972_CR12","doi-asserted-by":"publisher","first-page":"e0292507","DOI":"10.1371\/journal.pone.0292507","volume":"19","author":"K Miyake","year":"2024","unstructured":"Miyake K, et al. Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study. PLoS ONE. 2024;19(2):e0292507.","journal-title":"PLoS ONE"},{"issue":"4","key":"13972_CR13","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1093\/cid\/ciad474","volume":"78","author":"DB Chastain","year":"2024","unstructured":"Chastain DB, et al. Unintended Consequences: Risk of Opportunistic Infections Associated With Long-term Glucocorticoid Therapies in Adults. Clin Infect Dis. 2024;78(4):e37\u201356.","journal-title":"Clin Infect Dis"},{"key":"13972_CR14","doi-asserted-by":"crossref","unstructured":"Li J, Mu X, Li H, Liu X. Immune responses of different hosts to Pneumocystis infection. Eur Respir Rev. 2025;34(177).","DOI":"10.1183\/16000617.0247-2024"},{"issue":"10","key":"13972_CR15","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1093\/rheumatology\/kead063","volume":"62","author":"X Chen","year":"2023","unstructured":"Chen X, et al. High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2023;62(10):3302\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"13972_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13075-021-02606-8","volume":"23","author":"L Huang","year":"2021","unstructured":"Huang L, et al. High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center. Arthritis Res Ther. 2021;23(1):232.","journal-title":"Arthritis Res Ther"},{"key":"13972_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/1471-2466-14-182","volume":"14","author":"CW Chou","year":"2014","unstructured":"Chou CW, et al. The impact of concomitant pulmonary infection on immune dysregulation in Pneumocystis jirovecii pneumonia. BMC Pulm Med. 2014;14:182.","journal-title":"BMC Pulm Med"},{"issue":"10","key":"13972_CR18","first-page":"CD005590","volume":"2014","author":"A Stern","year":"2014","unstructured":"Stern A, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014;2014(10):CD005590.","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"13972_CR19","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.cmi.2023.04.015","volume":"29","author":"L Hansel","year":"2023","unstructured":"Hansel L, et al. How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia? Clin Microbiol Infect. 2023;29(8):1015\u201323.","journal-title":"Clin Microbiol Infect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13972-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:03:51Z","timestamp":1791810231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13972-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13972"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13972-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Third People\u2019s Hospital of Hangzhou (Approval Number: 2024KA143) in accordance with the Declaration of Helsinki. Written informed consent was waived due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approved by the Ethics Committee of the Third People\u2019s Hospital of Hangzhou(2024KA143)in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","label":"IRB approval status","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1788"}}